Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

被引：69

作者：

Berraondo, Pedro ^{[1
,2
,3
]}

Etxeberria, Inaki ^{[1
,2
]}

Ponz-Sarvise, Mariano ^{[2
,4
,5
]}

Melero, Ignacio ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Navarra, Ctr Appl Med Res CIMA, Immunol & Immunotherapy Program, Pamplona, Spain

[2] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain

[3] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

[4] CUN, Dept Oncol, Pamplona, Spain

[5] CUN, Dept Immunol, Pamplona, Spain

来源：

CLINICAL CANCER RESEARCH | 2018年 / 24卷 / 12期

关键词：

T-CELL TRANSFER; DOXORUBICIN; THERAPY;

D O I：

10.1158/1078-0432.CCR-18-0381

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNg. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. (C) 2018 AACR.

引用

页码：2716 / 2718

页数：3

共 11 条

[11] Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma [J].

Zhang, Ling ;

Morgan, Richard A. ;

Beane, Joal D. ;

Zheng, Zhili ;

Dudley, Mark E. ;

Kassim, Sadik H. ;

Nahvi, Azam V. ;

Ngo, Lien T. ;

Sherry, Richard M. ;

Phan, Giao Q. ;

Hughes, Marybeth S. ;

Kammula, Udai S. ;

Feldman, Steven A. ;

Toomey, Mary Ann ;

Kerkar, Sid P. ;

Restifo, Nicholas P. ;

Yang, James C. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2015, 21 (10) :2278-2288

← 1 2 →